Summary of COVID-19: How long will the rebound symptoms of COVID and Paxlovid last?

In this week’s summary, the latest scientific study on coronavirus shows that some long COVID-19 cases had a physical response to the still-existing SARS-CoV-2 virus and COVID who took Paxrovid for 5 days during treatment. -19 Suggests that patients may be showing rebound symptoms, which may be due to the need for longer treatment with the pill.

Some long COVID patients still have the virus in their blood

Some cases of long COVID-19 may be the immune system’s response to SARS-CoV-2 infection lurking somewhere in the body, suggesting new findings from small studies. ..

The researchers analyzed multiple plasma samples collected over time from 63 COVID-19 patients, including 37 who continued to develop COVID-19 for a long time. Peplomers from the surface of the virus were detectable for up to 12 months in the majority of people with long COVID-19, but were not present in plasma samples of patients who recovered without persistent symptoms. Peplomers that circulate in the blood can mean that “reservoir of active virus remains in the body,” the researchers said. Papers submitted to medRxiv Last week, prior to peer review. The exact location of the reservoir is not clear from this study. Researchers said they found the active virus in the gastrointestinal tract of children weeks after the first coronavirus infection, while others said the virus was “at multiple anatomical sites up to 7 months after the onset of symptoms.” Found genetic evidence.

If the results can be confirmed in a larger study, the presence of peplomers in the blood long after the initial infection may be one way to diagnose long COVID-19, the researchers said.

Paxlovid “rebound” patients may require longer treatment

Symptom rebound reported in some COVID-19 patients who took Pfizer’s antiviral drug Paxrovid Pill for 5 days was inadequately treated according to researchers who closely evaluated one such patient. May be the result of.

Study results show that Paxlovid can reduce the risk of COVID-19 hospitalization and death in high-risk patients by 89% if taken within 5 days of onset of symptoms. However, in some patients, viral levels and symptoms may improve after completing the Paxrovid course, and the mutant may develop resistance to dual-drug treatment, or the pills may somehow be in the patient’s. This has led to concerns that it may be weakening antibody resistance. However, when researchers isolated the Omicron BA.2 mutant from a rebounded patient and tested it in the laboratory, they found that it was sensitive to Paxlobid and that there were no mutations that reduced the efficacy of the drug. They also found that the patient’s antibodies could block the invasion of the virus and the infection of new cells.

The rebound of COVID-19 symptoms after Paxrovid treatment is likely due to insufficient drug reaching the infected cells to completely prevent the virus from making its own copy. The researchers say. A paper published on Monday for clinical infectious diseases. Also, different people may have different rates of metabolism and processing of the drug, and some may need to take it for more than 5 days.

After COVID-19, the child will have more symptoms, but less anxiety

Persistent health problems were slightly more common in children after COVID-19 than in children of similar age who avoided the virus, according to Danish researchers. Reported on Wednesday at The Lancet Child & Adolescent Health.. However, researchers found that the level of anxiety was higher in children who had never experienced COVID-19.

They said that 40% of infants with COVID-19 and 27% of uninfected companions experienced at least one symptom for more than 2 months. Persistent symptoms were seen in 38% with and without COVID-19 among children aged 4 to 11 years. And between the ages of 12 and 14, 46% of people with COVID-19 and 41% without it had long-term symptoms. The results are based on a survey of nearly 11,000 mothers of infected children and nearly 33,000 mothers of uninfected children.

Long-term COVID-19-related symptoms such as headache, mood swings, abdominal pain, and malaise are often experienced by otherwise healthy children, but infected children show longer-lasting symptoms, one-third. Showed new symptoms that developed after COVID-19. To the surprise of the researchers, children infected with COVID-19 had fewer psychological and social problems than children in the control group. They speculated that this may be due to the increased fear of unknown illnesses and restrictions on daily life in uninfected children to protect themselves from being infected by the virus.

Daily Sabah Newsletter

Keep up to date with what’s happening in Turkey, the region, and the world.

sign up

You can unsubscribe at any time. By signing up, you agree to our Terms of Service and Privacy Policy. This site is protected by reCAPTCHA and is subject to Google’s privacy policy and terms of use.